PriceTargets.com logo

Genelux - GNLX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.00
  • Forecasted Upside: 900.00%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.40 As of 04/26/2024 01:00 AM ET
▲ +0.08 (2.41%)

This chart shows the closing price for GNLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genelux Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNLX

Analyst Price Target is $34.00
▲ +900.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Genelux in the last 3 months. The average price target is $34.00, with a high forecast of $40.00 and a low forecast of $30.00. The average price target represents a 900.00% upside from the last price of $3.40.

This chart shows the closing price for GNLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Genelux. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$30.00Low
4/2/2024HC WainwrightLower TargetBuy ➝ Buy$35.00 ➝ $32.00Low
11/27/2023HC WainwrightInitiated CoverageBuy$35.00Low
11/24/2023BenchmarkLower TargetSpeculative Buy ➝ Speculative Buy$38.00 ➝ $30.00Low
10/30/2023Brookline Capital ManagementUpgradeHold ➝ BuyLow
9/12/2023Maxim GroupInitiated CoverageBuy$40.00Low
2/15/2023BenchmarkInitiated CoverageSpeculative Buy$10.00Low
(Data available from 4/28/2019 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/30/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/29/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024

Current Sentiment

  • 6 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Genelux logo
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Read More

Today's Range

Now: $3.40
Low: $3.22
High: $3.42

50 Day Range

MA: $5.67
Low: $3.32
High: $8.10

52 Week Range

Now: $3.40
Low: $3.07
High: $40.98

Volume

85,044 shs

Average Volume

142,876 shs

Market Capitalization

$91.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Genelux?

The following equities research analysts have issued stock ratings on Genelux in the last twelve months: Benchmark Co., Brookline Capital Management, HC Wainwright, and Maxim Group.
View the latest analyst ratings for GNLX.

What is the current price target for Genelux?

3 Wall Street analysts have set twelve-month price targets for Genelux in the last year. Their average twelve-month price target is $34.00, suggesting a possible upside of 900.0%. Maxim Group has the highest price target set, predicting GNLX will reach $40.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $30.00 for Genelux in the next year.
View the latest price targets for GNLX.

What is the current consensus analyst rating for Genelux?

Genelux currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GNLX will outperform the market and that investors should add to their positions of Genelux.
View the latest ratings for GNLX.

What other companies compete with Genelux?

Other companies that are similar to Genelux include Abeona Therapeutics, ProPhase Labs, PMV Pharmaceuticals, Allakos and DiaMedica Therapeutics. Learn More about companies similar to Genelux.

How do I contact Genelux's investor relations team?

Genelux's physical mailing address is 2625 Townsgate Road Suite 230, Westlake Village CA, 91361. The company's listed phone number is 805-267-9889 and its investor relations email address is [email protected]. The official website for Genelux is www.genelux.com. Learn More about contacing Genelux investor relations.